Skip to main content
SpringerLink
Log in

Therapy for Locoregional Disease: Stomach/Duodenum, Colon/Rectum

  • Chapter
  • First Online:
Neuroendocrine Tumors in Real Life

  • 581 Accesses

Abstract

Neuroendocrine neoplasms (NENs) of the gastrointestinal (GI) tract are a heterogeneous group of tumors originating from neuroendocrine cells distributed throughout the gut and frequently presenting with correlated hypersecretory syndromes, especially in metastatic diseases. Gut-derived NENs have been classified according to their embryological origin into tumors of the foregut (bronchi, stomach, pancreas, gallbladder, duodenum), midgut (duodenum, ileum, appendix, right colon), and hindgut (left colon, rectum).

The incidence of NENs diagnosed has increased in the last years, with GI primary tumors representing the majority of diagnosis. NENs may occur as part of complex familial endocrine cancer syndromes such as multiple endocrine neoplasia type 1 (MEN 1), multiple endocrine neoplasia type 2 (MEN 2), neurofibromatosis type 1, Von Hippel–Lindau syndrome, and Carney’s complex, although the majority occurs as sporadic isolated tumors.

The management of NENs of the GI tract in the setting of locoregional disease consists of different therapeutic approaches, in particular medical treatment and endoscopic procedures, and it varies greatly depending on the site of origin.

In patients with gastric NENs (gNENs), the approach depends on the clinical presentation of the tumor, classified in three types. Type 1 gNENs are associated with hypergastrinemia and chronic atrophic gastritis; the frequency of metastasis is low. Type 2 gNENs occur in patients with hypergastrinemia due to Zollinger-Ellison syndrome in combination with MEN 1. Type 3 gNENs are sporadic and have a more malignant course, frequently presenting with metastasis at the time of diagnosis.

Duodenal NENs are rare (less than 2% of all GI-NENs), and gastrinomas are the most frequent type of tumors originating in this site.

Rectal NENs are commonly small and generally low to intermediate grade (G1–2), whereas colonic NENs are often aggressive, poorly differentiated, and higher grade (G3).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Bibliography

  1. Burkitt MD, Pritchard DM (2006) Review article: pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther 24(9):1305–1320

    Article  CAS  PubMed  Google Scholar 

  2. Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E (1993) Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 104(4):994–1006

    Article  CAS  PubMed  Google Scholar 

  3. Waldum HL, Sandvik AK, Idle JR (1998) Gastrin is the most important factor in ECL tumorigenesis. Gastroenterology 114(5):1113–1115

    Article  CAS  PubMed  Google Scholar 

  4. Lehy T, Roucayrol AM, Mignon M (2000) Histomorphological characteristics of gastric mucosa in patients with Zollinger-Ellison syndrome or autoimmune gastric atrophy: role of gastrin and atrophying gastritis. Microsc Res Tech 48(6):327–338

    Article  CAS  PubMed  Google Scholar 

  5. Borch K, Ahren B, Ahlman H, Falkmer S, Granerus G, Grimelius L (2005) Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 242(1):64–73

    Article  PubMed  PubMed Central  Google Scholar 

  6. Borch K, Renvall H, Liedberg G (1985) Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 88(3):638–648

    Article  CAS  PubMed  Google Scholar 

  7. Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S, Stolte M, Capella C, Bordi C, Solcia E (1999) ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 116(3):532–542

    Article  CAS  PubMed  Google Scholar 

  8. Hosokawa O, Kaizaki Y, Hattori M, Douden K, Hayashi H, Morishita M, Ohta K (2005) Long-term follow up of patients with multiple gastric carcinoids associated with type A gastritis. Gastric Cancer (Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association) 8(1):42–46

    Google Scholar 

  9. Rindi G et al (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449:395–401

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Campana D, Nori F, Pezzilli R, Piscitelli L, Santini D, Brocchi E, Corinaldesi R, Tomassetti P (2008) Gastric endocrine tumors type I: treatment with long-acting somatostatin analogs. Endocr Relat Cancer 15(1):337–342

    Article  CAS  PubMed  Google Scholar 

  11. Campana D, Ravizza D, Ferolla P, Faggiano A, Grimaldi F, Albertelli M, Berretti D, Castellani D, Cacciari G, Fazio N, Colao A, Ferone D, Tomassetti P (2016) Clinical management of patients with gastric neuroendocrine neoplasms associated with chronic atrophic gastritis: a retrospective, multicentre study. Endocrine 51(1):131–139

    Article  CAS  PubMed  Google Scholar 

  12. Manfredi S, Pagenault M, de Lajarte-Thirouard AS, Bretagne JF (2007) Type 1 and 2 gastric carcinoid tumors: long-term follow-up of the efficacy of treatment with a slow-release somatostatin analogue. Eur J Gastroenterol Hepatol 19(11):1021–1025

    Article  PubMed  Google Scholar 

  13. Grozinsky-Glasberg S, Kaltsas G, Gur C, Gal E, Thomas D, Fichman S, Alexandraki K, Barak D, Glaser B, Shimon I, Gross DJ (2008) Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. European Journal of Endocrinology/European Federation of Endocrine Societies 159(4):475–482

    Article  CAS  Google Scholar 

  14. Jianu CS, Fossmark R, Syversen U, Hauso O, Fykse V, Waldum HL (2011) Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids. Scand J Gastroenterol 46(4):456–463

    Article  PubMed  Google Scholar 

  15. Peracchi M, Gebbia C, Basilisco G, Quatrini M, Tarantino C, Vescarelli C, Massironi S, Conte D (2005) Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids. European Journal of Endocrinology/European Federation of Endocrine Societies. 152(3):443–448

    Article  CAS  Google Scholar 

  16. Rappel S, Altendorf-Hofmann A, Stolte M (1995) Prognosis of gastric carcinoid tumours. Digestion 56(6):455–462

    Article  CAS  PubMed  Google Scholar 

  17. Hori K, Fukui H, Imura J, Kojima T, Fujita M, Kawamata H, Chiba T, Fujimori T (2000) Benign gastric carcinoid tumor with hypergastrinemia followed up for 12 years. Gastric Cancer (Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association) 3(3):161–164

    Google Scholar 

  18. Ravizza D, Fiori G, Trovato C, Fazio N, Bonomo G, Luca F, Bodei L, Pelosi G, Tamayo D, Crosta C (2007) Long-term endoscopic and clinical follow-up of untreated type 1 gastric neuroendocrine tumours. Dig Liver Dis 39(6):537–543

    Article  CAS  PubMed  Google Scholar 

  19. Merola E, Sbrozzi-Vanni A, Panzuto F, D'Ambra G, Di Giulio E, Pilozzi E, Capurso G, Lahner E, Bordi C, Annibale B, Delle FG (2012) Type I gastric carcinoids: a prospective study on endoscopic management and recurrence rate. Neuroendocrinology 95(3):207–213

    Article  CAS  PubMed  Google Scholar 

  20. Uygun A, Kadayifci A, Polat Z, Yilmaz K, Gunal A, Demir H, Bagci S (2014) Long-term results of endoscopic resection for type I gastric neuroendocrine tumors. J Surg Oncol 109(2):71–74

    Article  PubMed  Google Scholar 

  21. Ozao-Choy J, Buch K, Strauchen JA, Warner RR, Divino CM (2010) Laparoscopic antrectomy for the treatment of type I gastric carcinoid tumors. J Surg Res 162(1):22–25

    Article  PubMed  Google Scholar 

  22. Basuroy R, Srirajaskanthan R, Prachalias A, Quaglia A, Ramage JK (2014) Review article: the investigation and management of gastric neuroendocrine tumours. Aliment Pharmacol Ther 39(10):1071–1084

    Article  CAS  PubMed  Google Scholar 

  23. Delle Fave G, O'Toole D, Sundin A, Taal B, Ferolla P, Ramage JK, Ferone D, Ito T, Weber W, Zheng-Pei Z, De Herder WW, Pascher A, Ruszniewski P (2016) ENETS consensus guidelines update for Gastroduodenal neuroendocrine neoplasms. Neuroendocrinology 103(2):119–124

    Article  CAS  PubMed  Google Scholar 

  24. Lahner E, Esposito G, Pilozzi E, Galli G, Corleto VD, Di Giulio E, Annibale B (2015) Gastric cancer in patients with type I gastric carcinoids. Gastric Cancer (Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association) 18(3):564–570

    Google Scholar 

  25. Vannella L, Lahner E, Annibale B (2012) Risk for gastric neoplasias in patients with chronic atrophic gastritis: a critical reappraisal. World J Gastroenterol 18(12):1279–1285

    Article  PubMed  PubMed Central  Google Scholar 

  26. Grozinsky-Glasberg S, Thomas D, Strosberg JR, Pape UF, Felder S, Tsolakis AV, Alexandraki KI, Fraenkel M, Saiegh L, Reissman P, Kaltsas G, Gross DJ (2013) Metastatic type 1 gastric carcinoid: a real threat or just a myth? World J Gastroenterol 19(46):8687–8695

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Fykse V, Sandvik AK, Qvigstad G, Falkmer SE, Syversen U, Waldum HL (2004) Treatment of ECL cell carcinoids with octreotide LAR. Scand J Gastroenterol 39(7):621–628

    Article  CAS  PubMed  Google Scholar 

  28. Massironi S, Zilli A, Fanetti I, Ciafardini C, Conte D, Peracchi M (2015) Intermittent treatment of recurrent type-1 gastric carcinoids with somatostatin analogues in patients with chronic autoimmune atrophic gastritis. Dig Liver Dis 47(11):978–983

    Article  CAS  PubMed  Google Scholar 

  29. Thomas D, Tsolakis AV, Grozinsky-Glasberg S, Fraenkel M, Alexandraki K, Sougioultzis S, Gross DJ, Kaltsas G (2013) Long-term follow-up of a large series of patients with type 1 gastric carcinoid tumors: data from a multicenter study. European Journal of Endocrinology/European Federation of Endocrine Societies 168(2):185–193

    Article  CAS  Google Scholar 

  30. Oberg K (2012) Biotherapies for GEP-NETs. Best Pract Res Clin Gastroenterol 26(6):833–841

    Article  PubMed  Google Scholar 

  31. Moore AR, Boyce M, Steele IA, Campbell F, Varro A, Pritchard DM (2013) Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis. PLoS One 8(10):e76462

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Fossmark R, Sordal O, Jianu CS, Qvigstad G, Nordrum IS, Boyce M, Waldum HL (2012) Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin a. Aliment Pharmacol Ther 36(11–12):1067–1075

    Article  CAS  PubMed  Google Scholar 

  33. Kantsevoy SV, Adler DG, Conway JD, Diehl DL, Farraye FA, Kwon R, Mamula P, Rodriguez S, Shah RJ, Wong Kee Song LM, Tierney WM (2008) Endoscopic mucosal resection and endoscopic submucosal dissection. Gastrointest Endosc 68(1):11–18

    Article  PubMed  Google Scholar 

  34. Yamamoto H, Kawata H, Sunada K, Sasaki A, Nakazawa K, Miyata T, Sekine Y, Yano T, Satoh K, Ido K, Sugano K (2003) Successful en-bloc resection of large superficial tumors in the stomach and colon using sodium hyaluronate and small-caliber-tip transparent hood. Endoscopy 35(8):690–694

    Article  CAS  PubMed  Google Scholar 

  35. Ono H, Kondo H, Gotoda T, Shirao K, Yamaguchi H, Saito D, Hosokawa K, Shimoda T, Yoshida S (2001) Endoscopic mucosal resection for treatment of early gastric cancer. Gut 48(2):225–229

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Rosch T, Sarbia M, Schumacher B, Deinert K, Frimberger E, Toermer T, Stolte M, Neuhaus H (2004) Attempted endoscopic en bloc resection of mucosal and submucosal tumors using insulated-tip knives: a pilot series. Endoscopy 36(9):788–801

    Article  CAS  PubMed  Google Scholar 

  37. Gotoda T, Kondo H, Ono H, Saito Y, Yamaguchi H, Saito D, Yokota T (1999) A new endoscopic mucosal resection procedure using an insulation-tipped electrosurgical knife for rectal flat lesions: report of two cases. Gastrointest Endosc 50(4):560–563

    Article  CAS  PubMed  Google Scholar 

  38. Kim HH, Kim GH, Kim JH, Choi MG, Song GA, Kim SE (2014) The efficacy of endoscopic submucosal dissection of type I gastric carcinoid tumors compared with conventional endoscopic mucosal resection. Gastroenterol Res Pract 2014:253860

    PubMed  PubMed Central  Google Scholar 

  39. Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L (2000) Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med 343(8):551–554

    Article  CAS  PubMed  Google Scholar 

  40. Meko JB, Norton JA (1995) Management of patients with Zollinger-Ellison syndrome. Annu Rev Med 46:395–411

    Article  CAS  PubMed  Google Scholar 

  41. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, Tomasek J, Raderer M, Lahner H, Voi M, Pacaud LB, Rouyrre N, Sachs C, Valle JW, Delle Fave G, Van Cutsem E, Tesselaar M, Shimada Y, Oh DY, Strosberg J, Kulke MH, Pavel ME (2016) Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet 387(10022):968–977

    Article  CAS  PubMed  Google Scholar 

  42. Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, Dueland S, Hofsli E, Guren MG, Ohrling K, Birkemeyer E, Thiis-Evensen E, Biagini M, Gronbaek H, Soveri LM, Olsen IH, Federspiel B, Assmus J, Janson ET, Knigge U (2013) Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Annals of Oncology (Official Journal of the European Society for Medical Oncology/ESMO) 24(1):152–160

    Article  CAS  Google Scholar 

  43. Nikou GC, Toubanakis C, Moulakakis KG, Pavlatos S, Kosmidis C, Mallas E, Safioleas P, Sakorafas GH, Safioleas MC (2011) Carcinoid tumors of the duodenum and the ampulla of Vater: current diagnostic and therapeutic approach in a series of 8 patients. Case series. Int J Surg (London, England) 9(3):248–253

    Article  Google Scholar 

  44. Pipeleers-Marichal M, Donow C, Heitz PU, Kloppel G (1993) Pathologic aspects of gastrinomas in patients with Zollinger-Ellison syndrome with and without multiple endocrine neoplasia type I. World J Surg 17(4):481–488

    Article  CAS  PubMed  Google Scholar 

  45. Donow C, Pipeleers-Marichal M, Schroder S, Stamm B, Heitz PU, Kloppel G (1991) Surgical pathology of gastrinoma. Site, size, multicentricity, association with multiple endocrine neoplasia type 1, and malignancy. Cancer 68(6):1329–1334

    Article  CAS  PubMed  Google Scholar 

  46. Karagiannis S, Eshagzaiy K, Duecker C, Feyerabend B, Mozdzanowski E, Faiss S (2009) Endoscopic resection with the cap technique of a carcinoid tumor in the duodenal bulb. Endoscopy 41(Suppl 2):E288–E289

    Article  PubMed  Google Scholar 

  47. Dalenback J, Havel G (2004) Local endoscopic removal of duodenal carcinoid tumors. Endoscopy 36(7):651–655

    Article  CAS  PubMed  Google Scholar 

  48. Tai WP, Yue H (2009) Endoscopic mucosa resection of a duodenum carcinoid tumor of 1.2 cm diameter: a case report. Med Oncol (Northwood, London, England) 26(3):319–321

    Article  Google Scholar 

  49. Honda T, Yamamoto H, Osawa H, Yoshizawa M, Nakano H, Sunada K, Hanatsuka K, Sugano K (2009) Endoscopic submucosal dissection for superficial duodenal neoplasms. Digestive Endoscopy (Official Journal of the Japan Gastroenterological Endoscopy Society) 21(4):270–274

    Google Scholar 

  50. Matsumoto S, Miyatani H, Yoshida Y, Nokubi M (2011) Duodenal carcinoid tumors: 5 cases treated by endoscopic submucosal dissection. Gastrointest Endosc 74(5):1152–1156

    Article  PubMed  Google Scholar 

  51. De Palma GD, Masone S, Siciliano S, Maione F, Falleti J, Mansueto G, De Rosa G, Persico G (2010) Endocrine carcinoma of the major papilla: report of two cases and review of the literature. Surg Oncol 19(4):235–242

    Article  PubMed  Google Scholar 

  52. Crocetti E, Paci E (2003) Malignant carcinoids in the USA, SEER 1992-1999. An epidemiological study with 6830 cases. European Journal of Cancer Prevention (The Official Journal of the European Cancer Prevention Organisation (ECP)) 12(3):191–194

    Article  CAS  Google Scholar 

  53. Anthony LB, Strosberg JR, Klimstra DS, Maples WJ, O'Dorisio TM, Warner RR, Wiseman GA, Benson AB 3rd, Pommier RF (2010) The NANETS consensus guidelines for the diagnosis and management of gastrointestinal neuroendocrine tumors (nets): well-differentiated nets of the distal colon and rectum. Pancreas 39(6):767–774

    Article  PubMed  Google Scholar 

  54. Jetmore AB, Ray JE, Gathright JB Jr, McMullen KM, Hicks TC, Timmcke AE (1992) Rectal carcinoids: the most frequent carcinoid tumor. Dis Colon Rectum 35(8):717–725

    Article  CAS  PubMed  Google Scholar 

  55. Soga J (1997) Carcinoids of the rectum: an evaluation of 1271 reported cases. Surg Today 27(2):112–119

    Article  CAS  PubMed  Google Scholar 

  56. Son HJ, Sohn DK, Hong CW, Han KS, Kim BC, Park JW, Choi HS, Chang HJ, Oh JH (2013) Factors associated with complete local excision of small rectal carcinoid tumor. Int J Color Dis 28(1):57–61

    Article  Google Scholar 

  57. Park CH, Cheon JH, Kim JO, Shin JE, Jang BI, Shin SJ, Jeen YT, Lee SH, Ji JS, Han DS, Jung SA, Park DI, Baek IH, Kim SH, Chang DK (2011) Criteria for decision making after endoscopic resection of well-differentiated rectal carcinoids with regard to potential lymphatic spread. Endoscopy 43(9):790–795

    Article  CAS  PubMed  Google Scholar 

  58. Iishi H, Tatsuta M, Yano H, Narahara H, Iseki K, Ishiguro S (1996) More effective endoscopic resection with a two-channel colonoscope for carcinoid tumors of the rectum. Dis Colon Rectum 39(12):1438–1439

    Article  CAS  PubMed  Google Scholar 

  59. Boskoski I, Volkanovska A, Tringali A, Bove V, Familiari P, Perri V, Costamagna G (2013) Endoscopic resection for gastrointestinal neuroendocrine tumors. Expert Rev Gastroenterol Hepatol 7(6):559–569

    Article  CAS  PubMed  Google Scholar 

  60. Zhao ZF, Zhang N, Ma SR, Yang Z, Han X, Zhao YF, Gao F, Gong ZJ, Yang L (2012) A comparative study on endoscopy treatment in rectal carcinoid tumors. Surg Laparosc Endosc Percutan Tech 22(3):260–263

    Article  PubMed  Google Scholar 

  61. Kim KM, Eo SJ, Shim SG, Choi JH, Min BH, Lee JH, Chang DK, Kim YH, Rhee PL, Kim JJ, Rhee JC, Kim JY (2013) Treatment outcomes according to endoscopic treatment modalities for rectal carcinoid tumors. Clin Res Hepatol Gastroenterol 37(3):275–282

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical and Surgical Sciences, S.Orsola-Malpighi University Hospital, Bologna, Italy

    Davide Campana, Nico Pagano & Dario Fabbri

  2. Department of Experimental, Diagnostic and Specialty Medicine, S.Orsola-Malpighi University Hospital, Bologna, Italy

    Nicole Brighi & Guido Biasco

  3. Digestive and Liver Disease, Sapienza University of Rome, Sant’Andrea Hospital, Rome, Italy

    Maria Rinzivillo, Gianfranco Delle Fave & Francesco Panzuto

Authors
  1. Davide Campana
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nico Pagano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicole Brighi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dario Fabbri
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Maria Rinzivillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gianfranco Delle Fave
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Guido Biasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Francesco Panzuto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Davide Campana .

Editor information

Editors and Affiliations

  1. ENETs Center of Excellence for Neuroendocrine Tumours, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy

    Annamaria Colao

  2. ENETs Center of Excellence for Neuroendocrine Tumours, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy

    Antongiulio Faggiano

  3. Endocrine Oncology, Internal Medicine Department, Erasmus University, Rotterdam, Zuid-Holland, The Netherlands

    Wouter de Herder

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG

About this chapter

Cite this chapter

Campana, D. et al. (2018). Therapy for Locoregional Disease: Stomach/Duodenum, Colon/Rectum. In: Colao, A., Faggiano, A., de Herder, W. (eds) Neuroendocrine Tumors in Real Life. Springer, Cham. https://doi.org/10.1007/978-3-319-59024-0_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-59024-0_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-59022-6

  • Online ISBN: 978-3-319-59024-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation